Sanofi-Aventis Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

Sanofi-Aventis Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Sanofi-Aventis and its competitors. This provides our Clients with a clear understanding of Sanofi-Aventis position in the Pharmaceuticals and Biotechnology Industry.

Scope

• The report contains the company’s profile and data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.
• The SWOT-analysis provides information about the company’s strengths, weaknesses, opportunities, and possible threats against it.
• The report outlines the main financial ratios pertaining to profitability, margin analysis, asset turnover, credit ratios, and company’s long-term solvency.
• It also shows the company’s income statement and ratio trend-charts, with balance sheets and cash flows presented on an annual and quarterly basis.
• Company’s financial ratios are directly compared with those of its competitors through industry averages.
• The report provides relevant news, an analysis of PR-activity, and stock price movements.
• The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms.

The benefits of buying the Report are as follows:

• Readers will gain an unrivalled in-depth knowledge about the company.
• The report will help the management of your business environment. This will be achieved through the report’s unique analysis of both the market and company’s competitors, and by providing detailed information about the internal and external factors that affect the relevant industry.
• Your company’s business and sales activities will be boosted by gaining an insight into your competitors’ businesses.
• The report will help you to find prospective partners and suppliers.
• The annual profitability data provided in the report will assist and strengthen your company’s decision-making processes.

About Sanofi-Aventis

Sanofi-Aventis, a global pharmaceutical company, engages in the research, development, manufacture, and marketing of healthcare products.

Business

The company’s business includes two main activities: Pharmaceuticals and Human vaccines through sanofi pasteur. It is also present in animal health products through Merial Limited (Merial).

Pharmaceuticals

In the pharmaceutical activities, the company specializes in the following therapeutic areas:

Diabetes: The company’s products include Lantus, an analog of human insulin which is the main brand in the insulin market, Apidra, a rapid-acting analog of human insulin and Amaryl, an oral once-daily sulfonylurea;

Oncology: The company’s products in the oncology market are Taxotere, a taxane derivative representing a cornerstone therapy in several cancer types, and Eloxatine, a platinum agent, which is a treatment of colorectal cancer;

Thrombosis and Cardiovascular: The company’s thrombosis medicines include two drugs in their categories: Plavix, an anti-platelet agent indicated for atherothrombotic conditions, and Lovenox, a low molecular weight heparin indicated for prophylaxis, and treatment of deep vein thrombosis and for unstable angina and myocardial infarction. The company’s cardiovascular medicines include Multaq, a new anti-arrhythmic agent launched in the United States and other markets in 2009 and indicated for patients with atrial fibrillation, and two major hypertension treatments: Aprovel/ CoAprovel and Tritace;

Other therapeutic areas

Central Nervous System (CNS): The company’s major CNS medicines include Stilnox/Ambien CR, a sleep disorder prescription medication; Copaxone, an immunomodulating agent indicated in multiple sclerosis; and Depakine, an epilepsy treatment; and

Internal Medicine: In internal medicine, the company operates in various fields. In respiratory/allergy, the company’s products include Allegra, a non-sedating prescription anti-histamine, and Nasacort, a local corticosteroid indicated in allergic rhinitis. In urology, the company offers Xatral, a treatment for benign prostatic hypertrophy. In osteoporosis, it offers Actonel.

The portfolio of Sanofi-Aventis also comprises a range of other pharmaceutical products in Consumer Health Care (CHC) and other prescription drugs including generics.

Human Vaccines

The company offers pediatric combination vaccines providing protection against diseases, such as pertussis, diphtheria, tetanus, and Haemophilus influenzae type b infections. The company’s main products are Daptacel, Tripedia, Act-HIB, Pentacel, Pediacel, and Pentaxim/Pentavac. The company also produces injectable poliomyelitis (polio) vaccines, such as Ipol and Imovax Polio, as well as oral polio formulations, all of which contribute to polio eradication and disease control strategies in both developed and developing countries;

Influenza vaccines such as Fluzone and Vaxigrip, used for seasonal campaigns in both hemispheres, as well as Intanza/IDflu (the intradermal influenza vaccine, approved in Europe in February 2009), and Fluzone High Dose IM, approved in the U.S. in December 2009.

Additionally, the company manufactured and distributed: an A(H1N1) pandemic influenza vaccine in the United States; Panenza, another A(H1N1) pandemic influenza vaccine approved in several countries outside the United States, including in Europe; and pre-pandemic influenza vaccines (including H5N1 vaccines), as part of the global pandemic efforts in both French and U.S. facilities;

Adult and adolescent booster vaccines protecting against pertussis, tetanus, diphtheria and polio. The company’s main products include Adacel (the trivalent booster against pertussis, tetanus and diphtheria for adolescents and adults, launched in the U.S. in 2005), Adacel Polio, Decavac, Repevax and Revaxis;

Meningitis vaccines, with Menactra, a quadrivalent conjugate vaccine launched in the U.S. in 2005 and in Canada in 2006, Menomune, a quadrivalent polysaccharide vaccine, and a bivalent meningococcal A and C vaccine; and

Travel and Endemic vaccines, which include a range of products against hepatitis A, typhoid, rabies, yellow fever,

Contents

RESEARCH METHODOLOGY

DISCLAIMER

1. SANOFI-AVENTIS COMPANY PROFILE

1.1. Key facts
1.2. Financial Performance
1.3. Key Executives
1.4. Ownership and Major Holders
1.5. Company History

2. SANOFI-AVENTIS BUSINESS OVERVIEW

2.1. Business Description
2.2. Major Products and Services
2.3. Markets and Sales Activities
2.4. Locations, Subsidiaries, Operating Units

3. SANOFI-AVENTIS SWOT ANALYSIS

3.1. Overview
3.2. Strengths
3.3. Weaknesses
3.4. Opportunities
3.5. Threats

4. SANOFI-AVENTIS FINANCIAL ANALYSIS

4.1. Financial Statements
  4.1.1. Income Statement
  4.1.2. Balance Sheet
  4.1.3. Cash Flow
4.2. Financial Ratios
  4.2.1. Profitability
  4.2.2. Margin Analysis
  4.2.3. Asset Turnover
  4.2.4. Credit Ratios
  4.2.5. Long-Term Solvency
  4.2.6. Growth Over Prior Year
  4.2.7. Financial Ratios Charts
4.3. Stock Market Snapshot

5. SANOFI-AVENTIS COMPETITORS AND INDUSTRY ANALYSIS

5.1. Sanofi-Aventis Direct Competitors
5.2. Comparison of Sanofi-Aventis and Direct Competitors Financial Ratios
5.3. Comparison of Sanofi-Aventis and Direct Competitors Stock Charts
5.4. Sanofi-Aventis Industry Analysis
  5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
  5.4.2. Sanofi-Aventis Industry Position Analysis

6. SANOFI-AVENTIS NEWS & EVENTS

6.1. News & PR Activity Analysis
6.2. IR Corporate News
6.3. Marketing News
6.4. Corporate Events

7. SANOFI-AVENTIS EXPERTS REVIEW

7.1. Experts Opinion
7.2. Experts Estimates

APPENDIX 1: RATIO DEFINITIONS

LIST OF TABLES

Table 1. Sanofi-Aventis Key Facts
Table 2. Sanofi-Aventis Profitability
Table 3. Sanofi-Aventis Management Effectiveness
Table 4. Sanofi-Aventis Income Statement Key Figures
Table 5. Sanofi-Aventis Balance Sheet Key Figures
Table 6. Sanofi-Aventis Cash Flow Statement Key Figures
Table 7. Financial Performance Abbreviation Guide
Table 8. Sanofi-Aventis Key Executives
Table 9. Sanofi-Aventis Key Executives Biographies *
Table 10. Sanofi-Aventis Key Executives Compensations *
Table 11. Sanofi-Aventis Key Executives Stock Options *
Table 12. Sanofi-Aventis Major Shareholders
Table 13. Sanofi-Aventis History
Table 14. Sanofi-Aventis Products
Table 15. Sanofi-Aventis Revenues by Product
Table 16. Sanofi-Aventis Revenues by Region
Table 17. Sanofi-Aventis Offices and Representations
Table 18. Sanofi-Aventis SWOT Analysis
Table 19. Sanofi-Aventis Income Statement 2008-2011 Including 4-years Trends
Table 20. Sanofi-Aventis Income Statement Latest 4 Quarters Including Trends
Table 21. Sanofi-Aventis Balance Sheet 2008-2011 Including Trends
Table 22. Sanofi-Aventis Balance Sheet Latest 4 Quarters Including Trends
Table 23. Sanofi-Aventis Cash Flow 2008-2011 Including Trends
Table 24. Sanofi-Aventis Cash Flow Latest 4 Quarters Including Trends
Table 25. Sanofi-Aventis Profitability Ratios
Table 26. Sanofi-Aventis Margin Analysis Ratios
Table 27. Sanofi-Aventis Asset Turnover Ratios
Table 28. Sanofi-Aventis Credit Ratios
Table 29. Sanofi-Aventis Long-Term Solvency Ratios
Table 30. Sanofi-Aventis Financial Ratios Growth Over Prior Year
Table 31. Sanofi-Aventis Capital Market Snapshot
Table 32. Sanofi-Aventis Direct Competitors Key Facts
Table 33. Sanofi-Aventis Direct Competitors Profitability Ratios
Table 34. Sanofi-Aventis Direct Competitors Margin Analysis Ratios
Table 35. Sanofi-Aventis Direct Competitors Asset Turnover Ratios
Table 36. Sanofi-Aventis Direct Competitors Credit Ratios
Table 37. Sanofi-Aventis Direct Competitors Long-Term Solvency Ratios
Table 38. Pharmaceuticals and Biotechnology Industry Statistics
Table 39. Sanofi-Aventis Industry Position
Table 40. Sanofi-Aventis vs. Industry Income Statement Analysis
Table 41. Sanofi-Aventis vs. Industry Balance Sheet Analysis
Table 42. Sanofi-Aventis vs. Industry Cash Flow Analysis
Table 43. Sanofi-Aventis vs. Industry Ratios Comparison
Table 44. Sanofi-Aventis Consensus Recommendations*
Table 45. Sanofi-Aventis Analyst Recommendation Summary*
Table 46. Sanofi-Aventis Price Target Summary*
Table 47. Sanofi-Aventis Experts Recommendation Trends*
Table 48. Sanofi-Aventis Revenue Estimates Analysis*
Table 49. Sanofi-Aventis Earnings Estimates Analysis*
Table 50. Sanofi-Aventis Historical Surprises*
Table 51. Sanofi-Aventis Revenue Estimates Trend*
Table 52. Sanofi-Aventis Earnings Estimates Trend*
Table 53. Sanofi-Aventis Revenue Revisions*
Table 54. Sanofi-Aventis Earnings Revisions*

LIST OF FIGURES

Figure 1. Sanofi-Aventis Annual Revenues in Comparison with Cost of Goods Sold and Gross Profit
Figure 2. Sanofi-Aventis Profit Margin Chart
Figure 3. Sanofi-Aventis Operating Margin Chart
Figure 4. Sanofi-Aventis Return on Equity (ROE) Chart
Figure 5. Sanofi-Aventis Return on Assets (ROA) Chart
Figure 6. Sanofi-Aventis Debt to Equity Chart
Figure 7. Sanofi-Aventis Current Ratio Chart
Figure 8. Sanofi-Aventis 1-year Stock Charts
Figure 9. Sanofi-Aventis 5-year Stock Charts
Figure 10. Sanofi-Aventis vs. Main Indexes 1-year Stock Chart
Figure 11. Sanofi-Aventis vs. Direct Competitors 1-year Stock Charts
Figure 12. Sanofi-Aventis Article Density Chart

* – Data availability depends on company’s security policy.
The complete financial data is available for public traded companies.

The above Company Fundamental Report is a half-ready report.
It means that we have all necessary data in our database to prepare the report but need 2-3 days to complete it. During this time we are also updating the report with respect to the current moment. So, you can get up-to-date version for the same price.